project . 2019 - 2024 . On going

VASA

Vaccine Against Schistosomiasis for Africa. A Phase I clinical study of the SchistoShield® anti-schistosomiasis vaccine in adults in endemic areas of sub-Saharan Africa
Open Access mandate for Publications and Research DataOpen Access mandate for ... European Commission
  • Funder: European CommissionProject code: 815643 Call for proposal: H2020-SC1-2018-Two-Stage-RTD
  • Funded under: H2020 | RIA-LS Funder Contribution: 6,619,340 EUR
  • Status: On going
  • Start Date
    01 Jun 2019
    End Date
    31 May 2024
  • Detailed project information (CORDIS)
Description
Schistosomiasis is a poverty-related neglected tropical disease, impacting one billion people in 74 countries. Science ranked a schistosomiasis-vaccine as one of the top-10 vaccines urgently needed. Chemotherapy is the preferred method for schistosomiasis control; but the effectiveness of mass-treatment programs is compromised by reinfection requiring regular re-treatment. An efficacious vaccine, with long-lasting protection against all schistosomiasis forms, would impact disease control. We request funding for the clinical development of our SchistoShield®-vaccine (Sm- p80 antigen+GLA-SE adjuvant) in Burkina Faso and Madagascar, where Schistosoma mansoni (causi...
Description
Schistosomiasis is a poverty-related neglected tropical disease, impacting one billion people in 74 countries. Science ranked a schistosomiasis-vaccine as one of the top-10 vaccines urgently needed. Chemotherapy is the preferred method for schistosomiasis control; but the effectiveness of mass-treatment programs is compromised by reinfection requiring regular re-treatment. An efficacious vaccine, with long-lasting protection against all schistosomiasis forms, would impact disease control. We request funding for the clinical development of our SchistoShield®-vaccine (Sm- p80 antigen+GLA-SE adjuvant) in Burkina Faso and Madagascar, where Schistosoma mansoni (causi...
Any information missing or wrong?Report an Issue